000
| 01644cam 22002898a 4500 |
---|
001 | 9.865656 |
---|
003 | CaOODSP |
---|
005 | 20221107161841 |
---|
007 | cr ||||||||||| |
---|
008 | 181205t20192014onc #o f000 0 eng d |
---|
020 | |a9780660288628 |
---|
040 | |aCaOODSP|beng |
---|
043 | |an-cn--- |
---|
086 | 1 |aHP40-243/2018E-PDF |
---|
245 | 00|aLiterature review on the immunogenicity of herpes zoster vaccines |h[electronic resource]. |
---|
260 | |a[Ottawa] : |bPublic Health Agency of Canada, |c2019. |
---|
300 | |a46 p. |
---|
500 | |aIssued also in French under title: Revue de la littérature sur l'immunogénicité des vaccins contre le zona. |
---|
500 | |a"Publication date: January 2019." |
---|
500 | |a"An Advisory Committee Review (ACR), National Advisory Committee on Immunization (NACI)." |
---|
500 | |aCover title. |
---|
504 | |aIncludes bibliographical references. |
---|
520 | |a"Herpes zoster is an acute viral infection caused by reactivation of varicella-zoster virus (VZV). LZV, a live, attenuated vaccine for zoster has been available in Canada for many years. A new subunit recombinant zoster vaccine (RZV) named Shingrix was approved in Canada in October 2017. This zoster vaccine immunogenicity review was done to have a comprehensive understanding of the immunogenicity of both live and subunit vaccines"--Executive summary, p. 3. |
---|
692 | 07|2gccst|aImmunization |
---|
710 | 2 |aPublic Health Agency of Canada. |
---|
775 | 08|tRevue de la littérature sur l'immunogénicité des vaccins contre le zona |w(CaOODSP)9.865657 |
---|
856 | 40|qPDF|s1.56 MB|uhttps://publications.gc.ca/collections/collection_2019/aspc-phac/HP40-243-2018-eng.pdf |
---|